Cargando…
Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis
PURPOSE: While glucocorticoids (GCs) are effective in large vessel vasculitis (LVV), they may cause serious adverse events (AEs), especially if taken for longer durations and at higher doses. Unfortunately, patients suffering from LVV often need long-term treatment with GCs; therefore, toxicity need...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550368/ https://www.ncbi.nlm.nih.gov/pubmed/33047263 http://dx.doi.org/10.1007/s11926-020-00961-0 |
_version_ | 1783592961564475392 |
---|---|
author | Palmowski, Andriko Buttgereit, Frank |
author_facet | Palmowski, Andriko Buttgereit, Frank |
author_sort | Palmowski, Andriko |
collection | PubMed |
description | PURPOSE: While glucocorticoids (GCs) are effective in large vessel vasculitis (LVV), they may cause serious adverse events (AEs), especially if taken for longer durations and at higher doses. Unfortunately, patients suffering from LVV often need long-term treatment with GCs; therefore, toxicity needs to be expected and countered. RECENT FINDINGS: GCs remain the mainstay of therapy for both giant cell arteritis and Takayasu arteritis. In order to minimize their toxicity, the following strategies should be considered: GC tapering, administration of conventional synthetic (e.g., methotrexate) or biologic (e.g., tocilizumab) GC-sparing agents, as well as monitoring, prophylaxis, and treatment of GC-related AEs. Several drugs are currently under investigation to expand the armamentarium for the treatment of LVV. SUMMARY: GC treatment in LVV is effective but associated with toxicity. Strategies to minimize this toxicity should be applied when treating patients suffering from LVV. |
format | Online Article Text |
id | pubmed-7550368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-75503682020-10-19 Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis Palmowski, Andriko Buttgereit, Frank Curr Rheumatol Rep Recent Advances in Large Vessel Vasculitis ( C Dejaco and C Duftner, Section Editors) PURPOSE: While glucocorticoids (GCs) are effective in large vessel vasculitis (LVV), they may cause serious adverse events (AEs), especially if taken for longer durations and at higher doses. Unfortunately, patients suffering from LVV often need long-term treatment with GCs; therefore, toxicity needs to be expected and countered. RECENT FINDINGS: GCs remain the mainstay of therapy for both giant cell arteritis and Takayasu arteritis. In order to minimize their toxicity, the following strategies should be considered: GC tapering, administration of conventional synthetic (e.g., methotrexate) or biologic (e.g., tocilizumab) GC-sparing agents, as well as monitoring, prophylaxis, and treatment of GC-related AEs. Several drugs are currently under investigation to expand the armamentarium for the treatment of LVV. SUMMARY: GC treatment in LVV is effective but associated with toxicity. Strategies to minimize this toxicity should be applied when treating patients suffering from LVV. Springer US 2020-10-12 2020 /pmc/articles/PMC7550368/ /pubmed/33047263 http://dx.doi.org/10.1007/s11926-020-00961-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Recent Advances in Large Vessel Vasculitis ( C Dejaco and C Duftner, Section Editors) Palmowski, Andriko Buttgereit, Frank Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis |
title | Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis |
title_full | Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis |
title_fullStr | Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis |
title_full_unstemmed | Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis |
title_short | Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis |
title_sort | reducing the toxicity of long-term glucocorticoid treatment in large vessel vasculitis |
topic | Recent Advances in Large Vessel Vasculitis ( C Dejaco and C Duftner, Section Editors) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550368/ https://www.ncbi.nlm.nih.gov/pubmed/33047263 http://dx.doi.org/10.1007/s11926-020-00961-0 |
work_keys_str_mv | AT palmowskiandriko reducingthetoxicityoflongtermglucocorticoidtreatmentinlargevesselvasculitis AT buttgereitfrank reducingthetoxicityoflongtermglucocorticoidtreatmentinlargevesselvasculitis |